Teva launches AHZANTIVE, an Aflibercept biosimilar, across key European markets
Share
Teva Pharmaceutical (NYSE:TEVA) announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea, across several major European markets, including France, Germany, Spain, and the Netherlands.
